European Centre for Disease Prevention and Control

Slides:



Advertisements
Similar presentations
Surveillance of nosocomial infections Johnny, Courtesy, Brocolli.
Advertisements

European Surveillance of Surgical Site Infections and ICU-acquired Infections, Carl Suetens Surveillance Unit European Centre for Disease Prevention.
Overview ….. The extent of the problem of CAUTI
PREVENTION OF CATHETER ASSOCIATED URINARY TRACT INFECTIONS (CAUTIs)
Developing a Framework for Estimation of Healthcare-Associated Infection Burden at the National and State Level Matthew Wise, MPH, PhD Epidemiologist,
Antimicrobial Stewardship: an HAI response activity in Connecticut Richard Melchreit, MD HAI Program Coordinator.
HICC An Infection Control Committee provides a forum for multidisciplinary input and cooperation, and information sharing This committee should include.
Completing Ward List (Form A) & determining eligible patients for PPS PPS Data Collector Training April 2012 Presentation 2.
Skoog G, Cars O, Skärlund K, Elowson S, Hanberger H, Odenholt I, Prag M, Struwe J, Torell E, Ulleryd P, Erntell M STRAMA, Swedish Institute for Infectious.
Point Prevalence Survey of Hospital- Acquired Infections & Antimicrobial Use in Ireland PPS Data Collector Training April 2012 Antimicrobial Use & Case.
Information for Action Point Prevalence Survey of Healthcare associated infection and antimicrobial use 26 th June 2012 Dafydd Williams.
Implementation of Care Bundles at ward level
Hospital Surveillance. Impact of infectious diseases  IDs are considered to be the leading cause of death  Mass population movement  Emerging and re-emerging.
Case Report Form Start-up Meeting March 25, 2010 Kingston, ON.
STANDARDIZED INFECTION RATIO SIMPLIFIED
Tying it All Together Using EMRs to Support Quality Improvement 600 East Superior Street, Suite 404 I Duluth, MN I Ph or
QUESTIONS AND ANSWERS. A patient is admitted to the surveillance specialty with a catheter in situ Are they included in CAUTI surveillance?
MRSA and VRE. MRSA  1974 – MRSA accounted for only 2% of total staph infections  1995 – MRSA accounted for 22% of total staph infections  2004 – MRSA.
NOSOCOMIAL INFECTION SURVEILLANCE METHODS Masud Yunesian, M.D., Epidemiologist.
April 11 th 2014 Putting a S.T.O.P to traditional use of Invasive Devices: Use it or lose it! Liz Smith.
Fidelma Fitzpatrick Consultant Microbiologist, Health Protection Surveillance Centre & Beaumont Hospital, Dublin, Ireland HPSC, SARI and National HCAI.
PPS Data Collector Training April 2012
Point Prevalence Survey of Hospital- Acquired Infections & Antimicrobial Use in Ireland PPS Data Collector Training April 2012 Background & Introduction.
The epidemiology of HAI Scotland Dr Jacqui Reilly Consultant Epidemiologist Head of HAI and IC Group.
Measurement: the why, the what, and the how Paula Griswold, MPH Executive Director Massachusetts Coalition for the Prevention of Medical Errors Nora McElroy,
Erntell M, Skoog G, Cars O, Eriksson M, Skärlund K, Elowson S, Hanberger H, Odenholt I, Prag M, Struwe J, Torell E, Ulleryd P. STRAMA, Swedish Institute.
Indiana Healthcare Associated Infection Initiative Kickoff.
SICSAG Report 2013 Clinical Governance meeting. General information This report is based on critical care activity in the year Data collected on.
Improving the quality of medical and surgical care NCEPOD SEPSIS STUDY.
Part I BACKGROUND VENTILATOR ASSOCIATED PNEUMONIA.
Mary Andrus, BA, RN, CIC Division of Healthcare Quality Promotion
OVERVIEW AND COMPLETING THE QUESTIONNAIRES - Part 1 LECTURE 2.
The NHS Safety Thermometer 10 Steps to Success Series! Step 3 What is the NHS Safety Thermometer?
THE UTI MODULE LECTURE. To outline the aims of the UTI module To describe the questionnaires LECTURE OBJECTIVES.
Methodological challenges for AMR surveillance programmes Gous AGS, Pochee E School of Pharmacy Medical University of Southern Africa.
Version: 1.1 Dated: 04/10/ ,000 Days Campaign Dashboard September 2012 Campaign Manager : Diana Dowdle Clinical Leader: David Grayson Improvement.
PREPARING FOR PARTICIPATION IN HALT-2 LECTURE 6. To outline the steps necessary to prepare successfully for the HALT 2013 PPS. LECTURE OBJECTIVES.
Catheter Related Urinary Tract Infections
ECDC Point prevalence survey of healthcare- associated infections and antimicrobial use in acute care hospitals Forms V4.2.
Ward Name Date Ward Type No. Beds Sister Nurse No. Nurse Name Nurse exp. Patient No. Patient Name Bed No. Date Admitted Date ExpLeave. UNFINF2NF3NF.
Skoog G, Cars O, Skärlund K, Elowson S, Hanberger H, Odenholt I, Prag M, Struwe J, Torell E, Ulleryd P, Erntell M. STRAMA, Swedish Institute for Infectious.
Nosocomial infection Hospital acquired infections.
Insert name of presentation on Master Slide Health Care Associated Infections: Invasive Devices November 2011 Presenter: Liz Smith.
Kupu Taurangi Hauora o Aotearoa. Thank you to all people at the pilot sites who contributed Andrea McCance, Caroline Tilah, Cristina Ross, Fran Grocott,
Healthcare-associated infections & antimicrobial use in long-term care facilities (HALT) 2016 Training Day: Lecture 1 Welcome & Introduction to HALT 2016.
NOSOCOMIAL INFECTIons (HOSPITAL ACQUIRED INFECTIONS) by lovella d
Harm from Invasive Devices Dr. Eleri Davies, Faculty Lead HCAI.
Yousef I. Aljeesh, PhD, RN Said Abusalem, PhD, RN Naeem Alkariri, MSN, RN John A. Myers, PhD, MSPH Fawwaz Alaloul, PhD, RN Staff Developed IP Program Increases.
ECDC Point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals Forms V4.2.
ECDC Point Prevalence Survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2016–2017 Protocol v5.3 Forms.
PPS Data Collector Training April 2017
Antibiotics: handle with care!
Invasive Devices WebEx
ECDC Point Prevalence Survey of healthcare-associated infections and antimicrobial use in European acute care hospitals 2017 Belgian Forms.
Hospital acquired infections
Networks of hospitals: building a common strategy for HAI prevention and control and antimicrobial policy Tomasz Ozorowski, M.D. University of Medical.
2.13 Copyright UKCS #
Local organisation of the ECDC PPS
Reducing Mortality and Harm
Interpretation of local, national and European level results
ECDC point prevalence survey (PPS)
Data collection methods
Hospital organization, management, and structure for the infection prevention and control of healthcare-associated infection in Chinese hospitals:
Point prevalence survey epidemiology
* * * * * * * * * Form H: Hospital-based data by surveillance period
MRSA=Methicillin resistant Staphylococcus aureus
Ventilator Associated Pneumonia
Tony Crockford & Muhammad Sartaj.
Point prevalence survey (PPS) of healthcare associated infections (HAI) & antimicrobial use (AMU) in acute care Mark McConaghy, Dr Muhammad Sartaj,
Preventing Venous Thromboembolism Participating Hospital Survey
Presentation transcript:

European Centre for Disease Prevention and Control ECDC point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals Stockholm, May 2012

ECDC prevalence survey of healthcare-associated infections and antimicrobial use Form H. Hospital data Hospital code: Survey dates: From __ / __ /____ To: __ / __ / ____ dd/mm/yyyy dd/mm/yyyy Hospital size (total number of beds) Number of acute care beds Number of ICU beds Exclusion of wards for PPS? No Yes (please specify which ward types were excluded) _______________________________________________ Total number of beds in included wards: Total number of patients included in PPS: Hospital type: primary secondary tertiary specialised; please indicate specialisation type: ____________________________  Number Year data Inc. wards/ Total (1) No. of discharges/admissions in year   Inc=Tot No. of patient days in year Alcoholic hand rub consumption liters/year No. of patient rooms in hospital No. of single patient rooms in hospital No. of FTE infection control nurses No. of FTE infection control doctors (1) Data were collected for included wards (Inc = recommended) or for the total hospital (Tot); if all wards were included in PPS (Inc Tot), mark “Inc”. FTE = full-time equivalent Data apply to: Single hospital or hospital site Hospital trust or chain PPS Protocol: Standard Light Comments/observations: ___________________________ ______________________________________________ Below: To be filled in/checked by national coordinator Is the hospital part of a national representative sample of hospitals? No Yes Unknown

O current hospital O other hospital O other origin/unk ECDC prevalence survey of healthcare-associated infections and antimicrobial use Form A. Patient-based data (standard protocol) Antimicrobial (generic or brand name) Route Indication Diagnosis (site) Reason in notes   Patient data (to collect for all patients) Hospital code Ward name (abbreviated)/Unit ID Ward specialty Survey date: ___ / ___ / _______ (dd/mm/yyyy) Patient counter: _________________________________ Age in years: ____ years; age if < 2 years old: _____ months Sex: M F Date of hospital admission: ___ / ___ / _____ (dd/mm/yyyy) Consultant/patient specialty: Surgery since admission: O No surgery O Minimal invasive/non-NHSN surgery O NHSN surgery O Unknown McCabe score: O Non-fatal disease O Ultimately fatal disease O Rapidly fatal disease O Unknown Central vascular catheter: Peripheral vascular catheter: Urinary catheter: Intubation: Patient receives antimicrobial(s)(1): Patient has active HAI(2): Route: P: parenteral, O: oral, R: rectal, I: inhalation. Indication: CI - LI - HI: treatment intention for community-acquired (CI), long-/intermediate-term care-acquired (LI), or acute hospital-acquired infection (HI); surgical prophylaxis: SP1: single dose, SP2: one day, SP3: > one day; MP: medical prophylaxis; O: other; UI: unknown indication. Diagnosis: see site list, only for treatment intention. Reason in notes: Y/N. HAI 1 HAI 2 HAI 3 Case definition code   Relevant device in situ before onset(3) O Yes O No O Unknown O Yes O No Present at admission Date of onset(4) ___ / ___ / _____ Origin of infection O current hospital O other hospital O other origin/unk If BSI: source(5) MO code R(6) Microorganism 1 Microorganism 2 Microorganism 3 O No O Yes O Unk IF YES (1) At the time of the survey, except for surgical prophylaxis 24 hours before 8 a.m. on the day of the survey; if yes, fill in antimicrobial use data; (2) [infection with onset ≥ Day 3, OR SSI criteria met (surgery in previous 30 days/1 year), OR discharged from acute care hospital < 48 hours ago, OR CDI and discharged from acute care hospital < 28 days ago OR onset < Day 3 after invasive device/procedure on D1 or D2] AND [HAI case criteria met on survey day OR patient is receiving (any) treatment for HAI AND case criteria are met between D1 of treatment and survey day]; if yes, fill in HAI data. (3) Relevant device use (intubation for PN, CVC/PVC for BSI, urinary catheter for UTI) within 48 hours before onset of infection (even intermittent use), seven days for UTI. (4) Only for infections not present/active at admission (dd/mm/yyyy). (5) C-CVC, C-PVC, S-PUL, S-UTI, S-DIG, S-SSI, S-SST, S-OTH, UO, UNK. (6) AMR marker 0, 1, 2 or 9, see table.

Form B1. Ward denominator data (light protocol) ECDC prevalence survey of healthcare-associated infections and antimicrobial use Form B1. Ward denominator data (light protocol) Survey date1: ___ / ___ / _______ (dd/mm/yyyy) Hospital code Ward name (abbreviated)/Unit ID Ward specialty2 Total number of patients in ward3 Number of patients by consultant/patient specialty: Consultant/patient specialty Number of patients in ward3   1 Patients on the same ward should be included on a single day if possible. 2 Main ward specialty: ≥ 80% of patients belong to this specialty, otherwise choose mixed ward. 3 Admitted to the ward before or at 8 a.m. and not discharged from the ward at time of the survey.

O current hospital O other hospital O other origin/unk ECDC prevalence survey of healthcare-associated infections and antimicrobial use Form B2. Antimicrobial use and HAI data (light protocol) Antimicrobial (generic or brand name) Route Indication Diagnosis (site) Reason in notes   Patient data (patients with HAI and/or antimicrobial only) Hospital code Ward name (abbreviated)/Unit ID Patient counter: _________________________________ Age in years: ____ years; age if < 2 years old: _____ months Sex: M F Date of hospital admission: ___ / ___ / _____ (dd/mm/yyyy) Consultant/patient specialty: Patient receives antimicrobial(s)(1): O No O Yes Patient has active HAI(2): O No O Yes Route: P: parenteral, O: oral, R: rectal, I: inhalation. Indication: CI - LI - HI: treatment intention for community-acquired (CI), long-/intermediate-term care-acquired (LI), or acute hospital-acquired infection (HI); surgical prophylaxis: SP1: single dose, SP2: one day, SP3: > 1day; MP: medical prophylaxis; O: other; UI: unknown indication. Diagnosis: see site list, only for treatment intention. Reason in notes: Y/N. IF YES HAI 1 HAI 2 HAI 3 Case definition code   Relevant device in situ before onset(3) O Yes O No O Unknown O Yes O No Present at admission Date of onset(4) ___ / ___ / _____ Origin of infection O current hospital O other hospital O other origin/unk If BSI: source(5) MO code R(6) Microorganism 1 Microorganism 2 Microorganism 3 (1) At the time of the survey, except for surgical prophylaxis 24 hours before 8 a.m. on the day of the survey; if yes, fill antimicrobial use data; (2) [infection with onset ≥ Day 3, OR SSI criteria met (surgery in previous 30 days/1year), OR discharged from acute care hospital < 48 hours ago, OR CDI and discharged from acute care hospital < 28 days ago OR onset < Day 3 after invasive device/procedure on D1 or D2] AND [HAI case criteria met on survey day OR patient is receiving (any) treatment for HAI AND case criteria are met between D1 of treatment and survey day]; if yes, fill in HAI data. (3) Relevant device use (intubation for PN, CVC/PVC for BSI, urinary catheter for UTI) within 48 hours before onset of infection (even intermittent use), seven days for UTI; (4) Only for infections not present/active at admission (dd/mm/yyyy); (5) C-CVC, C-PVC, S-PUL, S-UTI, S-DIG, S-SSI, S-SST, S-OTH, UO, UNK; (6) AMR marker 0,1,2 or 9; see table.

Form N. National/regional data ECDC prevalence survey of healthcare-associated infections and antimicrobial use Form N. National/regional data Country code: _____ Network ID/data source: _____ Start date PPS: __ / __ /____ (dd/mm/yyyy) National/regional PPS coordination centre/institute: ___________________________________________________ National/regional PPS coordination programme/unit: Name: ____________________________________________ Website: __________________________________________  Number Year data Total no. of acute care hospitals (sites)   No. of hospital trusts or chains Total no. of beds in acute care hospitals Total no. of acute care beds No. of discharges/admissions, all No. of discharges/admissions, acute care beds only No. of patient days, all No. of patient days, acute care beds only Method of sampling/recruitment of hospitals (more than one answer possible): O representative systematic random sample O other representative sample O convenience sample (selection) O all hospitals invited O voluntary participation O mandatory participation Total number of hospitals in PPS: Light (unit-based) protocol ____ Standard (patient-based) protocol _____ Number of hospitals submitted to ECDC: Light (unit-based) protocol ____ Standard (patient-based) protocol _____ Comments/observations: _________________________________________________________________________________________ ______________________________________________________________________________________________________________